Caxton Associates LP Kodiak Sciences Inc. Transaction History

Caxton Associates LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.81 - $8.88 $206,031 - $380,365	-42,834 Reduced 48.1%	46,213 $286,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.05 $204,636 - $252,657	31,386 Added 54.43%	89,047 $637,000
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $387,107 - $639,212	-51,137 Reduced 47.0%	57,661 $446,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $9.48 $548,341 - $1.03 Million	108,798 New	108,798 $831,000
Q2 2020 Aug 14, 2020	SELL	$42.74 - $66.25 $198,185 - $307,201	-4,637 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$38.18 - $73.95 $177,040 - $342,906	4,637 New	4,637 $221,000

104

39.8M

7.6K

3.5K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $138M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Caxton Associates LP, based on Form 13F filings with the SEC.

Stay updated on Caxton Associates LP with notifications on news.